Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy.
OBJECTIVE
To measure the 8-hydroxy-2'-deoxyguanosine (8-OHdG) level in patients having active Graves ophthalmopathy (GO) and to compare this oxidative stress biomarker and the clinical evolution of patients after systemic corticosteroid treatment.


METHODS
In 8 euthyroid patients having active GO, we determined the 8-OHdG levels in urine before, during, and after intensive corticosteroid therapy. Clinical activity and ophthalmopathy index scores were assessed. Nine age- and sex-matched healthy volunteers served as control subjects.


RESULTS
The mean 8-OHdG level was statistically significantly increased in patients having active GO compared with that of controls (17.47 vs 5.97 ng/mg of creatinine, P < .001). During and after maximal systemic corticosteroid treatment, patients had statistically significantly lower mean 8-OHdG levels (7.19 and 10.18 ng/mg of creatinine, respectively) compared with the mean level before treatment. These changes were accompanied by decreases in clinical activity and ophthalmopathy index scores. The urinary 8-OHdG levels were subsequently elevated in 2 patients having recurrent active GO when corticosteroid therapy was tapered or withdrawn.


CONCLUSIONS
Oxidative stress may have a role in the pathogenesis of GO. Urinary 8-OHdG level can be used not only as a noninvasive biomarker of oxidative stress in patients having GO but also as an objective and quantitative parameter in the follow-up of patients during immunosuppressive treatment.
Tsai
Chieh-Chih
CC
Department of Ophthalmology, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan.
Kao
Shu-Ching
SC
Cheng
Ching-Yu
CY
Kau
Hui-Chuan
HC
Hsu
Wen-Ming
WM
Lee
Cheng-Feng
CF
Wei
Yau-Huei
YH
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000284:Administration, Oral; D000328:Adult; D015415:Biomarkers / Q000652:urine*; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000652:urine; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D049970:Graves Ophthalmopathy / Q000188:drug therapy* / Q000652:urine*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D011239:Prednisolone / Q000627:therapeutic use*
D015415:Biomarkers; D005938:Glucocorticoids; D000080242:8-Hydroxy-2'-Deoxyguanosine; D011239:Prednisolone; D003849:Deoxyguanosine